Insulin-dependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation

International Journal of Molecular Medicine

Volumn 28, Issue 3, 2011, Pages 455-462

  Hie, Mamiko ^a   Iitsuka, Natsumi ^a   Otsuka, Tomoyo ^a   Tsukamoto, Ikuyo ^a  

^a NARA WOMEN'S UNIVERSITY   (Japan)

Author keywords

catenin; Diabetes mellitus; Dkk1; IGF I; Osteoblastogenesis; Sost; Wnt signaling

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; BETA CATENIN; BONE MORPHOGENETIC PROTEIN 2; CATHEPSIN K; COLLAGEN; DEOXYPYRIDINOLINE; DICKKOPF 1 PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; MESSENGER RNA; OSTEOCALCIN; PROTEIN KINASE B; RECOMBINANT SOMATOMEDIN C; SCLEROSTIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STREPTOZOCIN; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METABOLISM; CELL COUNT; CONTINUOUS INFUSION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; INJECTION; INSULIN DEPENDENT DIABETES MELLITUS; METAPHYSIS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; TIBIA; URINARY EXCRETION;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; AMINO ACIDS; ANIMALS; BETA CATENIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEINS; CATHEPSIN K; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; GENETIC MARKERS; GLYCOGEN SYNTHASE KINASE 3; HOMEODOMAIN PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; OSTEOBLASTS; OSTEOCALCIN; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 79960020245     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.697     Document Type: Article

References (39)

1. Kemink SA, Hermus AR, Swinkels LM, Lutterman JA and Smals AG: Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 23: 295-303, 2000. (Pubitemid 30426548)
2. Schwartz AV: Diabetes mellitus: does it affect bone? Calcif Tissue Int 73: 515-519, 2003.
3. Janghorbani M, Van Dam RM, Willett WC and Hu FB: Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166: 495-505, 2007. (Pubitemid 47283633)
4. Szkudelski T: The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50: 537-546, 2001.
5. Botolin S, Faugere MC, Malluche H, Orth M, Meyer R and McCabe LR: Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Endocrinology 146: 3622-3631, 2005. (Pubitemid 41058134)
6. Herrero S, Calvo OM, Garcia-Moreno C, et al: Low bone density with normal bone turnover in ovariectomized and streptozotocin-induced diabetic rats. Calcif Tissue Int 62: 260-265, 1998. (Pubitemid 28127940)
7. Horcajada-Molteni MN, Chanteranne B, Lebecque P, et al: Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res 16: 958-965, 2001. (Pubitemid 32332307)
8. Hie M, Shimono M, Fujii K and Tsukamoto I: Increased cathepsin K and tartrate-resistant acid phosphatase expression in bone of streptozotocin-induced diabetic rats. Bone 41: 1045-1050, 2007. (Pubitemid 350116747)
9. Hie M, Yamazaki M and Tsukamoto I: Curcumin suppresses increased bone resorption by inhibiting osteoclastogenesis in rats with streptozotocin-induced diabetes. Eur J Pharmacol 621: 1-9, 2009.
10. Hie M and Tsukamoto I: Increased expression of the receptor for activation of NF-κB and decreased runt-related transcription factor 2 expression in bone of rats with streptozotocin-induced diabetes. Int J Mol Med 26: 611-618, 2010.
11. Marie PJ: Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys 473: 98-105, 2008.
12. Rosen V, Thies RS and Lyons K: Signaling pathways in skeletal formation: a role for BMP receptors. Ann NY Acad Sci 785: 59-69, 1996. (Pubitemid 26302105)
13. Ducy P, Zhang R, Geoffroy V, Ridall AL and Karsenty G: Osf2/ Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89: 747-754, 1997. (Pubitemid 27516177)
14. Komori T: Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 99: 1233-1239, 2006.
15. Harada S and Rodan GA: Control of osteoblast function and regulation of bone mass. Nature 423: 349-355, 2003. (Pubitemid 40852710)
16. Lee MH, Kim YJ, Kim HJ, et al: BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 278: 34387-34394, 2003.
17. Miyama K, Yamada G, Yamamoto TS, et al: A BMP-inducible gene, dlx5, regulates osteoblast differentiation and mesoderm induction. Dev Biol 208: 123-133, 1999. (Pubitemid 29149452)
18. Yavropoulou MP and Yovos JG: The role of the Wnt signaling pathway in osteoblast commitment and differentiation. Hormones (Athens) 6: 279-294, 2007.
19. Bennett CN, Longo KA, Wright WS, et al: Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 102: 3324-3329, 2005. (Pubitemid 40328044)
20. Ellies DL, Viviano B, McCarthy J, et al: Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 21: 1738-1749, 2006. (Pubitemid 46141229)
21. Krishnan V, Bryant HU and Macdougald OA: Regulation of bone mass by Wnt signaling. J Clin Invest 116: 1202-1209, 2006.
22. van Bezooijen RL, Svensson JP, Eefting D, et al: Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22: 19-28, 2007. (Pubitemid 46032593)
23. Graubert MD, Goldstein S and Phillips LS: Nutrition and somatomedin. XXVII. Total and free IGF-I and IGF binding proteins in rats with streptozocin-induced diabetes. Diabetes 40: 959-965, 1991.
24. Epstein S, Takizawa M, Stein B, et al: Effect of cyclosporin A on bone mineral metabolism in experimental diabetes mellitus in the rat. J Bone Miner Res 9: 557-566, 1994. (Pubitemid 24090339)
25. Romero DF, Bryer HP, Rucinski B, et al: Amylin increases bone volume but cannot ameliorate diabetic osteopenia. Calcif Tissue Int 56: 54-61, 1995.
26. Murata A, Yasuda T and Niimi H: Two cases of insulin-dependent diabetes mellitus under insulin treatment with slow height velocity: relationship of growth hormone-binding protein, metabolic control and growth. Acta Paediatr Jpn 36: 272-275, 1994. (Pubitemid 24178363)
27. Fowlkes JL, Thrailkill KM, Liu L, et al: Effects of systemic and local administration of recombinant human IGF-I (rhIGF-I) on de novo bone formation in an aged mouse model. J Bone Miner Res 21: 1359-1366, 2006. (Pubitemid 44300042)
28. Goto A and Tsukamoto I: Increase in tartrate-resistant acid phosphatase of bone at the early stage of ascorbic acid deficiency in the ascorbate-requiring Osteogenic Disorder Shionogi (ODS) rat. Calcif Tissue Int 73: 180-185, 2003. (Pubitemid 37082365)
29. Parfitt AM, Drezner MK, Glorieux FH, et al: Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595-610, 1987.
30. Stein GS, Lian JB, van Wijnen AJ, et al: Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 23: 4315-4329, 2004. (Pubitemid 38758597)
31. Botolin S and McCabe LR: Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol 209: 967-976, 2006. (Pubitemid 44665719)
32. Fowlkes JL, Bunn RC, Liu L, et al: Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus. Endocrinology 149: 1697-1704, 2008. (Pubitemid 351468337)
33. Lu H, Kraut D, Gerstenfeld LC and Graves DT: Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology 144: 346-352, 2003. (Pubitemid 36076124)
34. Botolin S and McCabe LR: Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology 148: 198-205, 2007. (Pubitemid 46021451)
35. Laviola L, Natalicchio A and Giorgino F: The IGF-I signaling pathway. Curr Pharm Des 13: 663-669, 2007.
36. Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A and Giorgino F: The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol 205: 201-210, 2010.
37. Bafico A, Liu G, Yaniv A, Gazit A and Aaronson SA: Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 3: 683-686, 2001. (Pubitemid 32624426)
38. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C and Niehrs C: Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391: 357-362, 1998. (Pubitemid 28093502)
39. van Bezooijen RL, Roelen BA, Visser A, et al: Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199: 805-814, 2004. (Pubitemid 38375200)